NOTV: AI 评分 40/100 — AI 分析 (4月 2026)

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries. The company also sells analytical instruments to the pharmaceutical development and contract research industries.

Key Facts: Price: $0.27 AI Score: 40/100 Sector: Healthcare

公司概况

概要：

Inotiv, Inc. (NOTV) offers comprehensive drug discovery and development services, coupled with specialized analytical instruments, positioning it as a key partner for pharmaceutical, chemical, and medical device companies seeking to navigate complex regulatory landscapes and accelerate research timelines.

NOTV是做什么的？

Founded in 1974 and headquartered in West Lafayette, Indiana, Inotiv, Inc., formerly known as Bioanalytical Systems, Inc., has evolved into a comprehensive provider of drug discovery and development solutions. The company operates through two primary segments: Contract Research Services and Research Products. The Contract Research Services segment delivers a suite of services, including screening, pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing. These services support pharmaceutical, chemical, and medical device companies in navigating the complex regulatory landscape and accelerating their research timelines. The Research Products segment focuses on the design, development, manufacturing, and marketing of in vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography and electrochemistry instruments platforms, and analytical products. Inotiv serves a global clientele, operating in the United States, rest of North America, the Pacific Rim, and Europe. Inotiv's agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program exemplifies its role in advancing innovative healthcare solutions. With a history spanning several decades, Inotiv has established itself as a trusted partner in the drug development ecosystem.

NOTV的投资论点是什么？

Inotiv presents a notable market position due to its comprehensive service offerings in the drug discovery and development space. The company's two-pronged approach, encompassing both contract research services and research product sales, diversifies its revenue streams and mitigates risk. With a market capitalization of $0.01 billion, Inotiv is positioned for growth as the pharmaceutical and biotechnology industries continue to expand. Key value drivers include the increasing demand for preclinical research services and the adoption of Inotiv's innovative in vivo sampling technologies. The company's agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program highlights its capabilities and potential for future partnerships. Investors should monitor Inotiv's ability to improve its profit margin, which currently stands at -13.4%, and capitalize on growth opportunities within the expanding drug development market.

NOTV在哪个行业运营？

Inotiv operates within the medical diagnostics and research industry, a sector experiencing steady growth driven by increasing healthcare expenditures and advancements in pharmaceutical research. The competitive landscape includes companies like BDSX, BEAT, BIAF, CELU, and FGEN, each vying for market share in specific niches. The demand for contract research services is rising as pharmaceutical companies seek to outsource preclinical and clinical trials to reduce costs and accelerate drug development timelines. Inotiv's focus on providing comprehensive solutions, including both research services and analytical instruments, positions it to capitalize on these trends and gain a competitive edge.

Medical - Diagnostics & Research

Healthcare

NOTV有哪些增长机遇？

Expansion of Contract Research Services: The global contract research organization (CRO) market is projected to reach $79.2 billion by 2027. Inotiv can capitalize on this growth by expanding its service offerings and geographic reach within its Contract Research Services segment. This includes investing in advanced technologies and expertise to meet the evolving needs of pharmaceutical and biotechnology companies. Timeline: Ongoing.
Increased Adoption of In Vivo Sampling Systems: The market for in vivo sampling systems is growing due to the increasing demand for real-time monitoring of drug effects in preclinical studies. Inotiv can drive adoption of its Culex family of automated in vivo sampling and dosing instruments by highlighting their benefits in terms of data quality, efficiency, and cost savings. Timeline: Ongoing.
Strategic Partnerships and Acquisitions: Inotiv can pursue strategic partnerships and acquisitions to expand its capabilities and market presence. This includes partnering with complementary service providers or acquiring companies with specialized expertise in areas such as toxicology, pathology, or bioanalysis. Timeline: Ongoing.
Geographic Expansion: Inotiv operates in the United States, rest of North America, the Pacific Rim, and Europe. Expanding into new geographic markets, particularly in Asia-Pacific, can provide significant growth opportunities. This includes establishing local offices, building relationships with key customers, and adapting its service offerings to meet the specific needs of each market. Timeline: Ongoing.
Development of New Analytical Instruments: Inotiv can invest in the development of new analytical instruments to address emerging needs in the pharmaceutical and biotechnology industries. This includes developing instruments for advanced applications such as proteomics, metabolomics, and genomics. Timeline: Ongoing.

Market Cap of $0.01 billion indicates a small-cap company with potential for growth.
P/E ratio of -0.21 reflects current losses but also potential for future earnings growth.
Gross Margin of 20.9% demonstrates the company's ability to generate revenue above the cost of goods sold.
Beta of 4.16 suggests high volatility compared to the market, indicating higher risk and potential reward.
The company operates through two segments, Contract Research Services and Research Products, diversifying its revenue streams.

NOTV提供哪些产品和服务？

Provides screening and pharmacological testing services.
Offers nonclinical safety testing services.
Provides formulation development services.
Ensures regulatory compliance for pharmaceutical products.
Conducts quality control testing services.
Develops and validates analytical methods.
Offers drug metabolism, bioanalysis, and pharmacokinetics testing.
Manufactures and markets in vivo sampling systems.

NOTV如何赚钱？

Generates revenue through contract research services provided to pharmaceutical, chemical, and medical device industries.
Sells analytical instruments and related accessories to research and development organizations.
Offers specialized testing services, including drug metabolism and bioanalysis.
Provides climate-controlled archiving services for customer data and samples.

Pharmaceutical companies
Chemical companies
Medical device companies
Contract research organizations
Academic research institutions

Specialized Expertise: Inotiv possesses deep expertise in drug discovery and development, providing a competitive advantage in the market.
Comprehensive Service Offering: The company offers a broad range of services, from early-stage screening to late-stage clinical trials, making it a one-stop shop for its customers.
Proprietary Technology: Inotiv's in vivo sampling systems and analytical instruments provide a technological edge over competitors.
Established Reputation: With a history spanning several decades, Inotiv has built a strong reputation for quality and reliability.

什么因素可能推动NOTV股价上涨？

Upcoming: Potential new partnerships with pharmaceutical companies to conduct preclinical toxicity studies.
Ongoing: Increasing demand for contract research services due to the growing pharmaceutical and biotechnology industries.
Ongoing: Adoption of Inotiv's in vivo sampling systems by research institutions and pharmaceutical companies.
Ongoing: Expansion of service offerings to include new areas of drug discovery and development.

NOTV的主要风险是什么？

Potential: Negative profit margin may deter investors and limit financial flexibility.
Potential: High beta indicates significant stock price volatility, which could lead to losses for investors.
Ongoing: Intense competition from other CROs and analytical instrument providers.
Potential: Regulatory changes could impact the drug development process and reduce demand for Inotiv's services.

NOTV的核心优势是什么？

Comprehensive service offerings in drug discovery and development.
Proprietary in vivo sampling systems and analytical instruments.
Established reputation and long-standing industry presence.
Experienced management team with deep expertise in the pharmaceutical industry.

NOTV的劣势是什么？

Negative profit margin (-13.4%) indicates financial challenges.
High beta (4.16) suggests significant stock price volatility.
Small market capitalization limits access to capital.
Dependence on the pharmaceutical industry, which is subject to regulatory changes and economic cycles.

NOTV有哪些机遇？

Expansion of contract research services to capitalize on the growing CRO market.
Increased adoption of in vivo sampling systems in preclinical studies.
Strategic partnerships and acquisitions to expand capabilities and market presence.
Geographic expansion into new markets, particularly in Asia-Pacific.

NOTV面临哪些威胁？

Intense competition from other CROs and analytical instrument providers.
Regulatory changes that could impact the drug development process.
Economic downturns that could reduce demand for research services.
Technological advancements that could render existing products and services obsolete.

NOTV的竞争对手是谁？

Biodesix, Inc. — Focuses on lung diagnostic solutions. — (BDSX)
HeartBeam, Inc. — Develops cardiac monitoring technology. — (BEAT)
BioAffinity Technologies, Inc. — Specializes in cancer diagnostics. — (BIAF)
Celularity, Inc. — Develops cellular medicines. — (CELU)
FibroGen, Inc. — Focuses on therapeutics for fibrotic diseases and anemia. — (FGEN)

Key Metrics

Price: $0.27 (-9.66%)
Market Cap: $10.0M
MoonshotScore: 40/100

Company Profile

CEO: Robert W. Leasure Jr.
Headquarters: West Lafayette, IN, US
Employees: 1,977
Founded: 1997

AI Insight

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries. They also sell analytical instruments to the pharmaceutical development and contract research industries.

常见问题

What does Inotiv, Inc. do?

Inotiv, Inc. is a contract research organization (CRO) and provider of research products that supports the drug discovery and development efforts of pharmaceutical, chemical, and medical device companies. The company operates through two segments: Contract Research Services, which offers a range of preclinical testing and regulatory compliance services, and Research Products, which designs, develops, and markets in vivo sampling systems and analytical instruments. Inotiv's comprehensive solutions help its customers accelerate research timelines, reduce costs, and navigate the complex regulatory landscape.

Is NOTV stock a good buy?

NOTV stock presents a mixed investment profile. While the company operates in a growing industry and offers comprehensive services, its negative profit margin and high beta raise concerns. the may be worth researching potential for future earnings growth and the company's ability to capitalize on growth opportunities. A thorough analysis of Inotiv's financial performance, competitive positioning, and growth strategy is essential before making an investment decision. The small market cap also indicates higher risk.

What are the main risks for NOTV?

The main risks for Inotiv include its negative profit margin, which indicates financial instability, and its high beta, which suggests significant stock price volatility. Intense competition from other CROs and analytical instrument providers poses a threat to the company's market share. Regulatory changes in the pharmaceutical industry could also impact demand for Inotiv's services. Additionally, economic downturns could reduce research spending and negatively affect the company's revenue.